346 results about "Virus inhibitors" patented technology

The utility model discloses a sampling test tube for virus inhibitor detection and analysis, which relates to the technical field of sampling test tubes and comprises a test tube outer tube, a test tube inner tube is arranged on the inner surface of the test tube outer tube, and a sealing assembly is in threaded connection with the upper portion of the outer surface of the test tube outer tube. A connecting ring and a discharging assembly are fixedly mounted on the lower surface of the test tube outer tube, the connecting ring is located on the outer side of the discharging assembly, and the discharging assembly comprises a discharging tube. According to the test tube, the anti-slip strips are arranged, so that the test tube can be attached to fingers conveniently, the second sealing cover can be held conveniently and rotated conveniently, the second sealing cover is separated from the discharge pipe under the action of threads of the second sealing cover and the discharge pipe, the discharge pipe is opened, and a sample flows out of the discharge pipe from the bottom of the outer tube of the test tube, so that discharge of the sample is facilitated; samples and fragments can be separated through a filter screen, a discharge pipe is sealed through a piston, and the sealing performance of the piston and a second sealing cover is further improved by arranging a second sealing ring.

The invention relates to the technical field of biological medicines, in particular to an umbilical cord source mesenchymal stem cell exosome preparation, a preparation method and application in preparation of osteoarthritis medicines. The preparation is prepared by the method. The method comprises the following steps: pretreating umbilical cord-derived mesenchymal stem cells by adopting a pretreating agent; removing the pretreatment agent, and carrying out gradient centrifugation treatment on the pretreated umbilical cord source mesenchymal stem cells to obtain exosome precipitate; and re-suspending the exosome precipitate in a buffer solution containing a protease inhibitor to obtain the umbilical cord source mesenchymal stem cell exosome preparation. The application refers to the application of the preparation in preparation of osteoarthritis drugs. The problems of low yield and functional heterogeneity of EXO obtained by a conventional culture method are solved.

The invention discloses application of domoic acid in preparation of a largemouth bass frog virus inhibitor. The domoic acid disclosed by the invention is relatively low in cytotoxicity, and has an obvious inhibition effect on micropterus salmoides frog virus compared with other microalgal toxins. Further exploration shows that after the micropterus salmoides frog virus is in direct contact with the domoic acid for 12 hours, the micropterus salmoides frog virus is irregular in shape and is completely bright white, so that the domoic acid has a direct destructive effect on the micropterus salmoides frog virus. And the domoic acid can inhibit the process of releasing the micropterus salmoides frog virus to the outside of the cells.

The present disclosure relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

The invention discloses a protein extracting solution and a protein extracting method of polysaccharide and polyphenol plant tissues, and is characterized in that the protein extracting solution comprises the following components in molar ratio: 180-250 parts of trihydroxymethyl aminomethane hydrochloride buffer solution, 200-300 parts of sugar, 45-55 parts of chlorate, 10-70 parts of beta-mercaptoethanol and 0.5-2 parts of protease inhibitor. The browning condition of the total protein solution obtained by the protein extraction formula is obviously weakened, which indicates that the oxidation of polyphenol is obviously inhibited, the release of protein in a tissue sample is facilitated, and the extracted protein effect is better.

The invention relates to the technical field of plant tissue extraction, in particular to an efficient extraction method and application of ginseng callus-derived exosomes, the extraction method comprises the following steps: S1, mixing ginseng callus with a PBS buffer solution, homogenizing and filtering to obtain a filtrate; s2, adding a protease inhibitor and a deep eutectic solvent into the filtrate, uniformly mixing, and standing to obtain a mixed solution; s3, centrifuging and filtering the mixed solution, and reserving supernate; s4, carrying out ultracentrifugation on the supernatant, collecting the precipitate, and resuspending with PBS to obtain a resuspension; and S5, further filtering the resuspension to obtain a filtrate, and storing at low temperature. The ginseng callus exosome extracted by the extraction method disclosed by the invention can be applied to preparation of drugs or cosmetics with anti-oxidation, anti-inflammatory and anti-aging effects, and the technical problems of low extraction efficiency, insufficient purity, complex extraction operation and poor stability of the extracted exosome in the existing exosome extraction technology can be effectively solved.

The invention relates to a lactam compound, a preparation method thereof and application of the lactam compound in medicine. Specifically, the invention relates to a lactam compound as shown in a general formula (I), a preparation method of the lactam compound, a pharmaceutical composition containing the lactam compound and application of the lactam compound serving as a 3CL protease inhibitor to treatment of 3CL protease activity related diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification. # imgabs0 #

The present invention relates to processes for preparing Compound (I):or a pharmaceutically acceptable salt or solvate thereof. Compound (I) and pharmaceutical compositions are useful as Respiratory Syncytial Virus (RSV) inhibitors.

The present invention provides compounds that are 3CL protease inhibitors and their use in the treatment / or prophylaxis of viral infections, such as coronavirus infections. Experiments prove that the compounds have a relatively strong inhibition effect on 3CL protease, and can block virus replication by inhibiting the activity of the virus main protease 3CL so as to achieve an antiviral treatment effect. The compound has a novel structure prospect for treating and / or preventing coronavirus infection.

The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

The invention discloses a combined reagent for detecting fungus (1-3)-beta-D glucan, a kit and a detection method of fungus (1-3)-beta-D glucan, and belongs to the technical field of biomedical detection. The serum sample treatment liquid comprises a carbonate buffer solution with the pH value of 9.5-10.5, bacillus licheniformis protease, CHAPS, a surfactant and a preservative. The protein denaturing agent stop buffer comprises a phosphate buffer, a protease inhibitor, BSA and other components. Under the mild weak alkaline condition, the combined action of protease and a denaturant is utilized, a fungus (1-3)-beta-D glucan antigen-antibody compound in serum is efficiently dissociated, an antibody is irreversibly inactivated, and meanwhile the antigen activity is kept. The method has the advantages of simple operation, no need of heating, centrifugation or strong corrosive reagents, high safety, no precipitation and no gel of the treated sample, and suitableness for subsequent immunological detection. The invention further provides a detection kit containing the solution and a corresponding detection method, and the detection accuracy and efficiency are remarkably improved.

The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

The present invention provides solubilizing agents that have been identified to efficiently solubilize non-polar protease inhibitors, while additionally stabilizing enzymes, preferably hydrolases, in a liquid environment. Further provided are methods for stabilizing and solubilizing a protease and protease inhibitor in a liquid composition comprising such solubilizing agents and methods for cleaning a soiled fabric or dishware using a liquid composition comprising such solubilizing agents.

Provided in the present application are a cyclic peptide mutant and use and product thereof for the preparation of a coronavirus inhibitor, belonging to the technical field of cyclic peptide drugs. The present application is optimized on the basis of the cyclic peptide 6L3-3P11R. The obtained cyclic peptide mutant can resist the enzyme digestion effect of pancreatic enzymes and exhibits further improved antiviral activity, which is of great significance for expanding antiviral applications of cyclic peptide drugs.

The invention belongs to the technical field of biology, and relates to an exosome preserving fluid and an exosome preserving method. The preservation solution comprises glycerol with the concentration of 4-6% (V / V), trehalose with the concentration of 0.5-1.5% (W / V), albumin with the concentration of 0.05-0.2% (W / V), a sterile protective agent with the concentration of 0.01-0.03% (W / V), vitamin E with the concentration of 0.05-0.1% (W / V), ethylenediamine tetraacetic acid with the concentration of 0.05-0.2 mM, a protease inhibitor with the concentration of 0.05-0.1 mM and a basic solvent of 0.1 M phosphate buffer solution. The invention relates to an exosome preserving fluid and an exosome preserving method which are extremely low in toxic effect on a human body and can effectively preserve exosomes and maintain biological activity of the exosomes.

The invention relates to a related substance of a coronavirus 3CLpro protease inhibitor compound as shown in a formula (IV), a preparation method of the related substance and application of the related substance as an impurity reference substance in detection of the related substance of the compound as shown in the formula (IV), and the scientificity and accuracy of impurity detection of the compound as shown in the formula (IV) can be effectively improved by taking the related substance as the reference substance. The impurity content of the compound of the formula (IV) and the preparation thereof can be effectively and conveniently monitored, and the quality of the compound of the formula (IV) and the preparation thereof is favorably controlled, so that the safety and effectiveness of the compound and the preparation thereof are ensured.

The invention belongs to the field of biological medicine, and particularly relates to a fusobacterium nucleatum FtsZ protease inhibitor and application thereof. On the basis of the idea of new use of old drugs, drugs approved by FDA are subjected to structure-based virtual screening and molecular dynamics simulation, and sorafenib, ponatinib, ceritinib and ibastine can be stably combined to active sites of fusobacterium nucleatum FtsZ protease; in-vitro experiments also show that sorafenib, ponatinib, ceritinib and ibastine are inhibitors with the fusobacterium nucleatum FtsZ protease, so that new antibacterial applications of sorafenib, ponatinib, ceritinib and ibastine are explored. The invention not only provides a new angle for antibiotic discovery, but also provides an example for rapid development of a novel FtsZ protease inhibitor.

The invention provides a virus-like vector lysis solution and a virus-like vector lysis method. The virus-like vector lysis solution comprises Tris, EDTA (Ethylene Diamine Tetraacetic Acid), NaCl, TritonX-100, sodium deoxycholate, SDS (Sodium Dodecyl Sulfate), Tween 20 and a protease inhibitor mixture. Cas9 protein is wrapped in the viroid vector; the acquisition method of the viroid vector comprises the step of transfecting plasmids containing a structural gene sequence for expressing the viroid vector into virus producing cells to obtain the viroid vector. The cracking method of the viroid vector comprises the following steps: S1, using: carrying out cracking treatment on a viroid vector solution by using the cracking solution; and S2, performing Cas9 protein content detection on substances released after the carrier is cracked. The invention establishes a formula of the special lysate for VLP and a corresponding cracking method, and ensures high cracking efficiency.

The present application discloses a myocardial N69 protein protective solution and a myocardial N69 protein detection kit. The present application designs a myocardial N69 protein protective solution, the ratio of which includes: 0.12% to 0.48% by mass of Tris-HCl buffer, 1% to 5% by mass of BSA or 0.1% to 0.5% by mass of caseinate sodium, 0.2% to 2% by mass of disodium EDTA, 5% to 20% by mass of trehalose, 0.02% to 0.06% by volume of a surfactant, and 0.08% to 0.12% by volume of a preservative, ProClin300; it also includes a protease inhibitor and a reducing agent. The present application also designs a myocardial N69 protein detection kit. The present application can effectively and long-term preserve N69 protein calibrants and can quickly and accurately detect N69 protein.

The application provides a whole-process cold-chain preservation method for fresh large yellow croaker, which is targeted to enzyme inhibition and gradient microenvironment regulation. The method provided by the application comprises the following steps: 1, soaking the freshly caught large yellow croaker in seawater containing endogenous protease inhibitor peptides of the large yellow croaker within 30 minutes after catching, and reducing the core temperature of the fish body to 3-4 DEG C; after the soaking is completed, the surface moisture of the fish body is blown dry with sterile wind; 2, packaging the large yellow croaker after the surface moisture of the fish body is blown dry, and storing the packaged large yellow croaker in an environment with a temperature of-0.5-1 DEG C and a relative humidity of 65%-75%, so as to realize the preservation of the fresh large yellow croaker. The method provided by the application can greatly improve the preservation effect, and the endogenous protease inhibitor peptides of the large yellow croaker do not destroy the nutritional components of the fish meat, do not change the original flavor, have no chemical preservative residues, meet the green food standard, and are safer than the existing chemical preservation and soaking preservation technologies.

The invention provides a cyclopeptide mutant, application of the cyclopeptide mutant in preparation of a coronavirus inhibitor and a product, and belongs to the technical field of cyclopeptide drugs. Optimization is carried out on the basis of the cyclopeptide 6L3-3P11R, the obtained cyclopeptide mutant can resist the enzyme digestion effect of pancreatin, the antiviral activity of the cyclopeptide mutant is further improved, and the cyclopeptide mutant has important significance in expanding the antiviral application of cyclopeptide drugs.

The invention relates to process development of a preparation prescription of a coronavirus 3CL protease inhibitor compound Iscartrevir and a preparation method of the coronavirus 3CL protease inhibitor compound Iscartrevir. By strictly screening and optimizing the formula, the preparation with a specific prescription ratio is obtained. According to the preparation, the medicine stability is improved, through the overall synergistic effect of the dry granulation step, in the preparation process of the medicine components, the flowing property of totally mixed materials is good, and the sticking problem is further solved. Meanwhile, the preparation is simple in production process, short in production period, energy-saving, efficient, low in cost and suitable for industrial mass production.

The invention relates to the field of medicinal chemistry, in particular to a tetrahydroisoquinoline papain-like protease inhibitor shown in a formula (I) and application thereof.

Provided herein are methods for treating or preventing a disease caused by an veterinary coronavirus in a non-human animal suffering from a coronavirus infection, in particular a feline coronavirus infection.

The invention belongs to the field of medicinal chemistry, and relates to carbonyl fused heterocyclic derivatives used as ubiquitin-specific protease inhibitors, in particular to a compound shown in the formula (I), an isomer thereof or pharmaceutically acceptable salt thereof.

The present invention provides the use of 4,3',5'-trihydroxy resveratrol compounds in the preparation of coronavirus 3CL protease inhibitors. The present invention discovers that 4,3',5'-trihydroxy resveratrol and its analogs have the activity of inhibiting coronavirus 3CL protease, and can play an anti-coronavirus role by inhibiting the activity of coronavirus 3CL protease. Among them, piceatannol, oxyresveratrol, physcion, 2,6,3',5'-tetrahydroxy stilbene, cis-tartriloside, 4-hydroxy resveratrol, and 4,3',5'-trihydroxy resveratrol have a half-maximal inhibitory concentration (IC50) against SARS-CoV and SARS-CoV-2 3CL proteases lower than 10 μM, showing good anti-coronavirus 3CL protease effect, effectively inhibiting the activity of coronaviruses, and can potentially be used for the prevention and / or treatment of coronavirus infections, and further for the preparation of drugs for the prevention and / or treatment of coronavirus infections.

The present invention provides methods for the prevention or treatment of Erectile dysfunction (ED) by administering SLPIs to animals, such as male humans. These methods can be administer together with vitamin D and / or phosphodiesterase 5 inhibitors.

Aspects of the present disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBD"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an outer surface of the core. In some cases, the protease inhibitor is a gligliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject administered the pharmaceutical dosage form. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., bacterial protease) to the large intestine (e.g., colon) and / or the small intestine of a subject.